Abstract
We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.
Keywords:
Clinical trial; Lobeglitazone; Randomised trial; Thiazolidinediones.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Blood Glucose / analysis
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Double-Blind Method
-
Female
-
Glycated Hemoglobin / analysis
-
Humans
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / therapeutic use*
-
Lipids / blood
-
Male
-
Middle Aged
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
Thiazolidinediones / adverse effects
-
Thiazolidinediones / therapeutic use*
Substances
-
Blood Glucose
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Lipids
-
Pyrimidines
-
Thiazolidinediones
-
lobeglitazone